By Karlee Weinmann ( July 1, 2013, 1:27 PM EDT) -- The private equity owners of Biomet Inc. are weighing their options for an exit from the medical device manufacturer they bought for $11.4 billion more than a half-decade ago, according to a Monday report from the Financial Times. Blackstone Group LP, KKR & Co. LP, Goldman Sachs & Co.'s private equity branch and Texas-based TPG Capital are planning for a dual-track sale, in which they will gauge whether a traditional buyout or an initial public offering would deliver the heftiest returns. As they prepare to close out the six-year-old investment, the firms have enlisted Goldman Sachs, Barclays PLC, Citigroup Inc., JPMorgan Chase & Co., Bank of America Corp. and Wells Fargo NA to steer their way....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
